伐多卡因 | 72005-58-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 伐多卡因
• 中文别名: 瓦朵卡因
• 英文名称: 3-(2-Methylpiperidyl)4',6'-dimethyl-o-propionanisidide
• 英文别名: vadocaine；N-(2-methoxy-4,6-dimethylphenyl)-3-(2-methylpiperidin-1-yl)propanamide
• CAS: 72005-58-4
• 化学式: C₁₈H₂₈N₂O₂
• 分子量: 304.433
• InChiKey: UJCARUGFZOJPMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-chloro-4',6'-dimethyl-o-propionanisidide 、 3-甲基哌啶 生成 hydrochloride of 3-(2-methyl piperidyl)-4',6'-dimethyl-o-propionanisidide 、 伐多卡因
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• Cyclic quaternary ammonium compounds
  申请人：——

  公开号：US20030166629A1

  公开（公告）日：2003-09-04

  In one aspect, the present invention concerns the use of certain cyclic quaternary ammonium compounds as active ingredient in the manufacture of a medicament for use in the treatment and/or prevention of cough in warm-blooded animals, including humans, such as compounds of formula (I) wherein n is an integer of from 0 to 4; R 1 and E are independently selected from —CH 2 —R 16 and a group represented by formula (II).

  在某方面，本发明涉及使用某些环状季铵化合物作为活性成分，制造用于治疗和/或预防温血动物，包括人类的咳嗽药物，如式（I）化合物，其中n为0至4的整数；R1和E分别选择自—CH2—R16和由式（II）表示的基团。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
  申请人：Vyteris, Inc.

  公开号：EP1586347A1

  公开（公告）日：2005-10-19

  Highly shelf-stable electrically assisted transdermal drug delivery systems for deliverir g epinephrine, typically with an anesthetic such as lidocaine, are provided along with methods for making the highly shelf-stable epinephrine-containing transdermal deliver device. Highly shelf-stable packaged electrode assemblies for transdermal delivery of epinephrine also are provided.

  提供了用于输送肾上腺素（通常与利多卡因等麻醉剂一起）的高货架稳定性电辅助透皮给药系统，以及制造高货架稳定性含肾上腺素透皮给药装置的方法。还提供了用于透皮给药肾上腺素的高货架稳定性包装电极组件。
• Hyaluronic acid composition
  申请人：Q-Med AB

  公开号：EP2484387A1

  公开（公告）日：2012-08-08

  The present invention relates to an injectable hyaluronic acid composition comprising a hyaluronic acid; a local anesthetic selected from the group consisting of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative. The present invention further relates to the medical and non-medical, such as cosmetic, use of such a composition, and to a method of manufacturing such a composition.

  本发明涉及一种可注射的透明质酸组合物，该组合物包括透明质酸；一种局麻药，该局麻药选自由酰胺类和酯类局麻药组成的组或其组合；以及一种抗坏血酸衍生物。本发明还涉及这种组合物的医疗和非医疗用途，如美容用途，以及制造这种组合物的方法。